Inhibition of frusemide-induced hyperreninaemia by growth-hormone release-inhibiting hormone in man.
In a study of the effect of somatostatin (growth-hormone release-inhibiting hormone) on plasma-renin in healthy volunteers, plasma-renin activity was measured by radioimmunoassay after the intravenous administration of somatostatin and also during frusemide-induced hyperreninaemia. While somatostatin was being given, basal values of renin were unchanged. Injection of frusemide alone produced hyperreninaemia; but, under somatostatin, renin release was inhibited by 45%. The results indicate that somatostatin is a potent inhibitor of renin and exerts its effect independent of sodium excretion, which was unchanged under somatostatin. Conceivably, somatostatin plays an important role in the regulation of endogenous renin release.
D000328:Adult; D003864:Depression, Chemical; D004336:Drug Antagonism; D013006:Growth Hormone / Q000097:blood; D006801:Humans; D007263:Infusions, Parenteral; D007275:Injections, Intravenous; D008297:Male; D011188:Potassium / Q000652:urine; D011863:Radioimmunoassay; D012083:Renin / Q000097:blood*; D012964:Sodium / Q000652:urine; D013004:Somatostatin / Q000008:administration & dosage / Q000494:pharmacology*; D000092502:Renin Inhibitors
D013006:Growth Hormone; D011188:Potassium; D012083:Renin; D012964:Sodium; D013004:Somatostatin; D000092502:Renin Inhibitors